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ABSTRACT
Metastasis is major cause of mortality in patients with ovarian cancer. MiR-373 
has been shown to play pivotal roles in tumorigenesis and metastasis; however, a 
role for miR-373 in ovarian cancer has not been investigated. In this study, we show 
that the miR-373 expression is down-regulated in human epithelial ovarian cancer 
(EOC) and inversely correlated with clinical stage and histological grade. Ectopic 
overexpression of miR-373 in human EOC cells suppressed cell invasion in vitro and 
metastasis in vivo, and the epithelial–mesenchymal transition process. Silencing the 
expression of miR-373 resulted in an increased migration and invasion of EOC cells. 
Using integrated bioinformatics analysis, gene expression arrays, and luciferase 
assay, we identified Rab22a as a direct and functional target of miR-373 in EOC 
cells. Expression levels of miR-373 were inversely correlated with Rab22a protein 
levels in human EOC tissues. Rab22a knockdown inhibited invasion and migration 
of EOC cells, increased E-cadherin expression, and suppressed the expression of 
N-cadherin. Moreover, overexpression of Rab22a abrogated miR-373-induced invasion 
and migration of EOC cells. Taken together, these results demonstrate that miR-373 
suppresses EOC invasion and metastasis by directly targeting Rab22a gene, a new 
potential therapeutic target in EOC.
INTRODUCTION
Ovarian cancer is the leading cause of cancer 
deaths from gynecological malignancy in Western 
countries. According to the American Cancer Society, 
in 2013, 22,240 new cases of ovarian cancer and 14,230 
deaths due to ovarian cancer were reported in the US. 
Despite great advances in chemotherapy and surgical 
treatment of this disease, 70 to 90% of women with 
ovarian cancer develop relapse or metastasis, and the 
5-year survival rate of patients with advanced ovarian 
cancer who have peritoneal metastasis remains at 
approximately 30% [1]. The overall prognosis for patients 
with ovarian cancer is a consequence of aggressive 
metastatic behavior. Ovarian cancer is more likely to 
metastasize via intraperitoneal (i.p.) dissemination than 
via hematogenous or lymphatic routes. Factors involved 
in the pathogenesis of ovarian cancer metastasis include 
metastasis suppressor genes (Nm-23, Kiss-1, KAI1, 
E-cadherin, BRMS1), epithelial-mesenchymal transition 
(EMT), tumor microenvironment, chemokines, and 
anoikis resistance have been identified [2–7]. In addition 
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to those signaling molecules and cytokines, recent 
findings have shown that non-protein-coding RNAs, 
especially microRNAs (miRNAs) are often deregulated 
in ovarian cancer and are involved in the tumorigenesis 
and progression of ovarian cancer [8]. The miRNAs are 
endogenous 19–25 nt noncoding RNAs that can bind 
the 3'-untranslated region (3'-UTR) of specific genes to 
inhibit the translation of target gene, and an individual 
miRNA can target up to 200 target transcripts. While 
the number of known human miRNAs is continuously 
increasing, the roles of most of these miRNAs in human 
physiological and pathological processes remain to be 
elucidated. The miRNAs are usually dysregulated and 
function either as tumor suppressors or oncogenes in the 
initiation and progression of human carcinomas, including 
ovarian cancer [9]. Few miRNAs, such as miR-200 
family [10, 11], let-7 family [11], miR-21 [12] and 
miR-214 [13] have been studied for their roles in ovarian 
cancer carcinogenesis.
Previously, we examined miRNA expression 
profiles between ovarian cancer cells and the stem-like 
ovarian cancer-initiating cells (OCICs) [14] and identified 
deregulated miRNAs highly related to the metastatic 
capability of OCICs (our unpublished observations). 
Among those, miR-373 was frequently down-regulated 
in OCICs and ovarian cancer cells, although the role of 
miR-373 in ovarian cancer was not clear. In this study, 
we investigated the potential tumor suppressor effect of 
miR-373 in ovarian cancer. We identified a direct target 
of miR-373, Rab22a, which is a member of the Rab 
family of small GTPases. We show for the first time that 
the miR-373/Rab22a axis contributes to migration and 
invasion in ovarian cancer and may represent a potential 
therapeutic target for the disease.
RESULTS
MiR-373 is down-regulated in ovarian cancer 
tissues and cell lines and associated with tumor 
invasion and metastasis
Previous studies have indicated that miR-373 was 
frequently down-regulated in colon cancer [15] and hilar 
cholangiocarcinoma [16]. To explore the expression and 
significance of miR-373 in ovarian cancer carcinogenesis, 
the expression of miR-373 was detected in 30 primary 
epithelial ovarian cancer (PEOC) samples and 15 benign 
epithelial ovarian tumor tissues using TaqMan quantitative 
RT-PCR analysis. The expression of miR-373 was down-
regulated (P = 0.0104) in PEOC compared to benign tumor 
(Table 1). The expression of miR-373 was remarkably 
lower (P = 0.0124) in advanced tumor stages (III, IV) 
in which lymph node or distant metastases were present 
compared to earlier tumor stages; furthermore, differences 
(P < 0.05) in miR-373 expression among histological 
differentiation (G1 vs. G2-3) were observed (Table 1). 
These results suggested a possible association between 
down-regulation of miR-373 and metastastic EOC. In 
addition to PEOC, miR-373 expression was detected in 
ovarian immortal cell line IOSE and a panel of ovarian 
cancer cell lines cells (Fig. 1A). Compared to the IOSE 
cells, the expression of miR-373 was significantly down-
regulated in A2780, CP70, HeyC2, and SKOV3 cell 
lines. Furthermore, among these EOC cells, the lowest 
endogenous expression of miR-373 was observed in 
SKOV3 cells and the highest expression of miR-373 
was observed in A2780 cells (Fig. 1A). Given the above 
results, we decided to use the SKOV3 and A2780 cells for 
the below experiments.
Table 1: Clinicopathological features of ovarian tissue with regard to the relative expression 
of miR-373
Clincal characteristic N miR-373 expression P value
Benign 15 0.9209 ± 0.2135 0.0104
Malignant 30 0.2444 ± 0.05615
Age
 <50 13 0.1984 ± 0.06737
0.8080
 >50 17 0.2252 ± 0.08398
FIGO stage
 I-II 8 0.2316 ± 0.06109
0.0124
 III-IV 22 0.05472 ± 0.01749
Histology
 G1 20 0.2249 ± 0.06201
0.0474
 G2-G3 10 0.09251 ± 0.03231
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Figure. 1: miR-373 is frequently down-regulated in ovarian cancer cell lines and miR-373 inhibits the invasion and 
metastasis of SKOV3 cells in vitro and in vivo. (A) Compared to the IOSE cells, the expression of miR-373 was significantly down-
regulated in all four EOC cell lines. The expression of miR-373 was the lowest in SKOV3 cells. EOC, epithelial ovarian cancer; IOSE, 
immortalized nontumorigenic human ovarian surface epithelial; *p < 0.05 and **p < 0.01. (B) SKOV3 cells express high level of miR-373 
after transfection with pMSCV-miR-373 compared to the mock control, ***p < 0.001. (C) The effect of miR-373 on morphological changes 
of SKOV3 cells. More rounded epithelial-like morphology was observed in the miR-373-transfected-SKOV3 cells (bottom), while spindle-
shaped mesenchymal-like morphology was observed in the mock control cells (top). (D) E-cadherin (epithelial marker) augmentation and 
N-cadherin (mesenchymal marker) reduction in SKOV3 after the expression of miR-373. (E-F) Transwell invasion and migration assays 
of SKOV3 cells expressing miR-373 or mock control. Representative images (×100) are shown on the left and the quantification of five 
randomly selected fields is shown on the right. The invasive and migratory potential of miR-373-expressing cells showed a strong reduction 
compared with mock controls. (G) Decreased cellular migration in miR-373-transfected SKOV3 cells was confirmed by wound scratch 
assay. (H-I) Representative bioluminescent images of disseminated tumor in nude mice i.p. injected with SKOV3luc-pMSCV-miR-373 
cells (bottom) and SKOV3luc-pMSCV-NC cells (top), respectively. (J) The anatomical location of metastatic tumors upon macroscopic 
examination reflected bioluminescence and the number of metastatic tumor between two groups was significantly different, **p < 0.01.
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Ectopic overexpression of miR-373 suppresses 
EOC cell metastasis and invasion in vitro 
and in vivo
To better understand the impact of miR-373 on 
EOC cells, a lentivirus vector expressing miR-373 
(pMSCV-miR-373) was constructed and SKOV3-
transfected cells were established. As shown in Fig.1B, 
SKOV3 cells expressed high level of miR-373 after 
transfection with pMSCV-miR-373 compared to the 
mock control (P < 0.001). After stable transfection, 
miR-373-expressing SKOV3 cells displayed a change 
from spindle-shaped mesenchymal-like morphology 
to more rounded epithelial-like morphology (Fig. 1C). 
No morphological changes were observed in cells 
transfected with the negative control. Concurrent with 
the morphological changes, levels of E-cadherin were 
higher while levels of N-cadherin were lower (P < 0.01) 
in miR-373-transfected cells relative to cells transfected 
with the negative control (Fig. 1D), suggesting that the 
overexpression of miR-373 was associated with EMT and 
EOC cell metastasis. To further examine this possibility, 
an in vitro cell invasion assay was performed and the 
number of cells migrating through the Matrigel® matrix 
was counted. The invasive capacity of SKOV3-miR-373 
cells was reduced (P <  0.01) compared to vector-only 
cells (Fig. 1E) and the ability of miR-373-transfected cells 
to invade was suppressed (55%) compared with vector-
only cells. Boyden chamber assays without Matrigel 
further demonstrated that expression of miR-373 reduced 
(P < 0.01) migration of SKOV3 cells when compared 
with vector-only cells (Fig. 1F). In addition, result of the 
wound scratch assay showed reduced migration capability 
of miR-373-transfected cells by approximately 49% 
(Fig. 1G). However, ectopic expression of miR-373 had no 
effect on SKOV3 cell proliferation and colony formation 
in vitro (data not shown). Taken together, these results 
suggest that miR-373 is a negative metastatic regulator 
for EOC.
To evaluate the role of miR-373 in tumor invasion 
and metastasis in vivo, disseminated ovarian cancer was 
generated by injecting female nude mice with human 
SKOV3luc-pMSCV-miR-373 cells i.p. for the therapeutic 
group, while SKOV3luc-pMSCV-NC cells for the control 
group. A panel of representative images is shown 
in Fig. 1H-I. At 5 weeks of i.p. injection, miR-373-
transfected SKOV3luc cells formed fewer metastasis to 
organs in the peritoneal cavity compared to the control 
group, as the number of metastatic tumors in the 
pMSCV-miR-373 therapeutic group was 3.25 ± 0.31 and 
11.0 ± 1.98 in the pMSCV-NC control group (P = 0.005) 
(Fig. 1J). The SKOV3luc-pMSCV-miR-373-injected mice 
showed fewer incidence of metastasis in distant organ 
sites, whereas SKOV3-pMSCV-NC-injected mice showed 
metastatic deposits in the peritoneal wall, small intestine, 
colon, stomach, liver and diaphragm.
miR-373 directly regulated Rab22a activity
To investigate the potential target gene which 
miR-373 could regulate in ovarian cancer cells, 
microarray gene expression profiling of SKOV3-pMSCV-
miR-373 cells and SKOV3-pMSCV-NC cells was 
performed. The results in two independent experiments 
showed that 262 transcripts, including 168 downregulated 
transcripts and 94 upregulated transcripts, were impacted 
by overexpression of exogenous miR-373 in SKOV3 
cells (Supple Table 1). Data suggested that miR-373 
acts as a tumor suppressor in EOC, therefore a set of 
168 downregulated transcripts, which are potential 
direct targets of miR-373, was focused on for further 
experiments. Three bioinformatics-based prediction 
analysis softwares (PicTar, TargetScan, and miRanda) 
were used to identify the potential miR-373 targets. 
Of the 12 downregulated transcripts and potential 
targets of miR-373 (ANK2, CD44, CROT, ELAVL2, 
FN1, GALNT3, GNPDA2, PFN2, Rab22a, RND3, 
TGFBR1, and TGFBR2), CD44 [17], TGFBR1 [18], 
and TGFBR2 [19] have been reported as the direct 
miR-373 targets. To validate the other nine candidates, 
dual luciferase reporter assays were performed using 
constructs in which these targeting sites were cloned 
into the 3′-UTR of the renilla luciferase reporter gene 
(psiCHECK™-2). Transfection of cells with pMSCV-
miR-373, resulted in reduced (P < 0.05) luciferase 
activities of CROT, ELAVL2, GALNT3, GNPDA2, 
and Rab22a compared to controls (Fig. 2A). Additional 
examination of these five genes using quantitative RT-PCR 
analysis showed that only Rab22a was downregulated in 
SKOV3-miR-373-transfected cells (Fig. 2B).
To further examine Rab22a as a direct target gene 
of miR-373, SKOV3 and A2780 cells were transfected 
with pMSCV-miR-373 and anti-miR-373 inhibitor, 
respectively. Both mRNA and protein expression 
of Rab22a were substantially decreased after ectopic 
miR-373 transfection in SKOV3 cells (Fig. 2C). While 
diverse phenomena were observed, the Rab22a mRNA 
and protein levels were down-regulated by anti-miR-373 
inhibitor in A2780 cells (Fig. 2D). Dual luciferase reporter 
assays confirmed that the luciferase activities of Rab22a 
3'-UTR were significantly reduced in SKOV3 cells stably 
transfected with pMSCV-miR-373 and the luciferase 
activities increased in A2780 cells transfected with anti-
miR-373 inhibitor (Fig. 2E). Based on the bioinformatics 
prediction analysis, three miR-373-targeting sequences 
were identified in the 3'-UTR of Rab22a mRNA (Fig. 2F), 
and mutant vectors of Rab22a 3'-UTR containing four 
mutated bases on the predicted binding sites were 
constructed. Transient transfection of SKOV3 cells with 
the above wild-type or mutant vectors and miR-373 or 
mock control resulted in partial rescue of the inhibition 
(Fig. 2G), further supporting that Rab22a is a direct target 
of miR-373.
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Figure 2: miR-373 directly regulates Rab22a in SKOV3 cells. (A) Luciferase reporter assay was used to reveal 3'-UTRs of 
five candidate miR-373 targets (CROT, ELAVL2, GALNT3, GNPDA2, and Rab22a). (B) Quantitative RT-PCR was used to validate that 
only Rab22a was down-regulated in miR-373-transfected cells out of these five candidate genes. *p < 0.05, **p < 0.01 and ***p < 0.001. 
(C-D) Quantitative RT-PCR and Western blot analyses were performed to examine the effects of over- and under-expressed miR-373 on 
Rab22a gene expression in SKOV3 and A2780 cells, respectively. (E) Relative luciferase activity of Rab22a 3'-UTR in SKOV3 cells stable 
with or without overexpression of miR-373 and in A2780 cells transfected with anti-miR-373 inhibitor or negative control. (F) Putative 
miR-373 binding sequence in the 3′-UTR of Rab22a mRNA. (G) Relative activity of the luciferase gene fused with the wild-type or mutant 
3'-UTR of Rab22a. *P < 0.05, **P < 0.01.
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Rab22a is down-regulated in EOC tissues and 
promotes tumor cells invasion and metastasis
Previous reports indicated that the expression of 
Rab22a is increased in different cancer types, including 
liver cancer [20] and malignant melanoma [21], 
suggesting an oncogenic role for Rab22a. However, 
such a role for Rab22a in human EOC cells has not 
been investigated. IHC analysis was used to measure the 
expression of Rab22a protein in 30 cases of EOC tissue, 
15 cases of benign ovarian tumor tissues and 10 cases of 
normal ovarian tissues. The expression of Rab22a protein 
was significantly up-regulated in EOC tissues when 
compared with those in benign tumor and normal ovarian 
tissues (Fig. 3A). Increased expression of Rab22a was 
observed in advanced tumor stages (III, IV), indicating 
that expression of Rab22a was positively correlated with 
FIGO stage (P = 0.027). No significant differences were 
observed based on patients’ age (<50 years vs. >50 years) 
and histology (Fig. 3B). The overexpression of Rab22a 
in EOC tissues was strongly correlated with reduced 
expression of miR-373, suggesting that the increased 
expression of Rab22a might result from down-regulation 
of miR-373 in human EOC.
To explore the biological functions of Rab22a in 
ovarian cancer cells, endogenous expression of Rab22a 
Figure 3: Rab22a is often overexpressed in human EOCs. (A) Representative images of IHC staining for Rab22a in benign 
ovarian tumor and EOC tissues (×100 and ×400). (B) Clinicopathological features of ovarian tissue with regard to the relative expression 
of Rab22a. IHC = immunohistochemistry.
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was knocked down in SKOV3 cells with specific siRNA 
(pLenti-shRab22a) (Fig. 4A). Rab22a knockdown 
was associated with reduced (P < 0.05) cell migration 
and invasion (Fig. 4B), increased expression of 
epithelial marker E-cadherin and decreased expression 
of mesenchymal marker N-cadherin (Fig. 4C). 
Ectopic overexpression of Rab22a in SKOV3 cells 
reversed these molecular changes, resulting in 
down-regulation of E-cadherin and up-regulation of 
N-cadherin (Fig. 4D).
Figure 4: Rab22a can significantly promote migration and invasion of EOC cells. (A) Quantitative RT-PCR and Western blot 
analyses were performed to examine depressing the expression of Rab22a in SKOV3 cells after stably transfected with pLenti-shRab22a. 
(B) Transwell invasion and migration assays of SKOV3 cells transfected with Rab22a-siRNA or negative control were performed to 
investigate the effects of Rab22a on migration and invasion of EOC cells. (C-D) Western blot analysis was used to assay the expression 
level of E-cadherin and N-cadherin in SKOV3 cells after transfection with Rab22a-siRNA or pCMV6-Rab22a, *P < 0.05, **P < 0.01.
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MiR-373 directly targets Rab22a to suppress 
EMT-mediated migration and invasion in EOC
To examine a possible role for Rab22a in 
miR-373-mediated suppression of EOC migration and 
invasion, specific siRNAs against Rab22a were used. As 
siRab22a-2 inhibited Rab22a protein more efficiently than 
siRab22a-1 (Supple Fig.1), co-transfection experiments 
using siRab22a-1 or siRab22a-2 and anti–miR-373 
were carried out. Inhibition of miR-373 expression was 
unable to increase cell invasion and migration in Rab22a-
depleted A2780 cells (Fig. 5A-B), and western blot 
analysis showed that E-cadherin was positively regulated 
and N-cadherin was negatively regulated in A2780 cells 
co-transfected with anti-miR-373 and siRab22a 
(Fig. 5C). On the other hand, overexpression of Rab22a 
abrogated (P < 0.05) miR-373-mediated invasion and 
migration of SKOV3 cells (Fig. 5D-E), and E-cadherin 
was negatively regulated and N-cadherin was positively 
regulated in SKOV3 cells co-transfected with pCMV-
miR-373 and pCMV6-Rab22a (Fig. 5F). The down-
regulation of Rab22a was strongly correlated with 
the over-expression of miR-373 in xenograft ovarian 
carcinoma metastatic models in nude mice by SKOV3luc-
pMSCV-miR-373 cells (Fig. 5G). Taken together, these 
results support the hypothesis that miR-373, by targeting 
Rab22a, regulates EOC migration and invasion.
DISCUSSION
Recent studies have shown that miRNAs play 
a fundamental role in the invasion and metastasis of 
malignant cancers [22], including EOC [8]. Previous 
studies identified miR-373 as an oncogene that is 
up-regulated in a number of different human tumor 
types, including medullary thyroid carcinoma [23], 
hepatocellular carcinoma [24, 25], prostate cancer [26], 
gastric cancer [27], and testicular germ cell tumors [28]. 
However, in breast cancer miR-373 appears to have tumor 
suppressor activity, as re-expression of miR-373 inhibited 
TGF-β-induced invasion in MDA-MB-231 and MCF10A 
cells as well as vascular intravasation in ER- breast cancer 
in vivo [19]. Chen et al. reported that down-regulation of 
miR-373 in hilar cholangiocarcinoma is associated with 
poor cell differentiation, advanced clinical stage, and 
shorter survival [15]. However, little is known about the 
role and underlying molecular mechanism of miR-373 in 
EOC, therefore the present study represents the first report 
on miR-373 in a panel of EOC cell lines and patient ovarian 
cancer tissues. Moreover, re-expression of miR-373 in 
ovarian cancer cells results in decreased cellular migration 
and invasion in vitro and in vivo. Taken together, these 
data suggest that miR-373 acts as a tumor suppressor 
in EOC, which is in agreement with those previous 
findings on this miR in breast cancer. MiR-373 belongs 
to miRNAs-371-373 clusters, located at chromosome 
19q13.42 and matured from pri-miRNAs-371-373. Recent 
studies have shown that rearrangements of chromosomal 
band 19q13.4 represent a frequent clonal cytogenetic 
deviation in thyroid adenomas [29] and prostate cancer [30]. 
MiR-373 is located in close proximity to these 
chromosomal rearrangements and several groups 
recently have linked the expression of miR-373 with 
the genomic alteration [30]. Tanaka [16] and Chen [15] 
et al. reported that the expression of miR-373 is down-
regulated by aberrant methylation in colon cancer and hilar 
cholangiocarcinoma, and our future studies will examine 
the possible mechanism(s) regulating miR-373 expression 
in EOC.
Our current study identified that Rab22a was a 
direct target of miR-373 in EOC. Down-regulation of 
miR-373 in EOC cells resulted in increased expression 
of Rab22a, resulting in enhanced EOC migration and 
invasion. Transient expression of miR-373 and siRNA-
based knockdown of Rab22a showed essentially similar 
effects in ovarian cancer cells, further confirming that 
direct targeting of Rab22a by miR-337 plays an important 
inhibitory role in migration and invasion of ovarian 
cancer cells. Rab22a, a small GTPase, is a member of 
the Rab family endocytic pathway [31]. Previous reports 
showed that Rab22 recruits Rabex-5 (a guanine nucleotide 
exchange factor (GEF) for activation of Rab5) on early 
endosomes and activates Rab5, establishing a Rab22–
Rabex-5–Rab5 cascade that is functionally important 
for the endocytosis and degradation of epidermal growth 
factor. Rab5 was reported to play key roles in the 
migration of cancer cells through the integrin-mediated 
signaling pathway [32–34]. Recently, Hu et al. found 
activation of Rab5 could promote TGF-β signaling [35] 
and it is increasingly apparent that TGF-β and 
TGF-β-related proteins have emerged as major inducers of 
epithelial-mesenchymal transition process in development 
and cancer. These findings shed new light on the model 
in which miR-373 may suppress TGF-β signaling through 
Rab22–Rabex-5–Rab5 cascade. Overexpression of 
Rab22a has been observed previously in liver cancer [20] 
and MM cell lines [21], suggesting an oncogenic role for 
Rab22a in tumorigenesis. We demonstrate that Rab22a 
is significantly up-regulated in human EOC tissues and 
overexpression of Rab22a in EOC cells may result from 
down-regulation of miR-373. Enforced over-expression of 
miR-373 down-regulate Rab22a expression in EOC cells, 
while Rab22a knockdown reduce EOC cells migration and 
invasion. Furthermore, Rab22a overexpression resulted 
in down-regulation of E-cadherin and up-regulation of 
N-cadherin in OC cells, indicating a novel mechanism 
underlying migration and invasion of EOC cells.
In summary, the present study is the first to 
demonstrate a tumor suppressor role for the miR-373 by 
targeting Rab22A in human EOC. The miR-373/Rab22a 
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Figure 5: miR-373 suppressed EMT-related migration and invasion via directly targeting Rab22a in ovarian 
cancer cells. (A-B) Transwell invasion assays and migration assays for A2780 cells after co-transfected with anti-miR-373 inhibitor 
and siRab22a. (C) Immunoblotting of E-cadherin and N-cadherin in A2780 cells co-transfected with anti-miR-373 inhibitor and siRab22a. 
(D-E) Transwell invasion assays and migration assays for SKOV3 cells after co-transfected with miR-373 and Rab22a. (F) Immunoblotting 
of E-cadherin and N-cadherin in SKOV3 cells co-transfected with miR-373 and Rab22a, *P < 0.05, **P < 0.01. (G) The down-regulation 
of Rab22a was strongly correlated with the over-expression of miR-373 in ovarian carcinoma metastatic models constructed in nude mice 
by SKOV3luc-pMSCV-miR-373 cells.
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axis provides a novel insight into the pathogenesis of EOC, 
particularly EOC invasion and metastasis, and represents 
a new potential therapeutic target for the treatment of this 
deadly malignancy.
MATERIALS AND METHODS
Cell lines and human tissue samples
The human epithelial ovarian cancer (EOC) cells 
(SKOV3, A2780, and CP70) were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA) 
and were cultured in RPMI-1640 (Gibco, Foster City, CA) 
supplemented with 10% (w/v) fetal bovine serum (FBS; 
Gibco) and 1% penicillin-streptomycin (Gibco). Human 
ovarian immortalized nontumorigenic human ovarian 
surface epithelial (IOSE) and EOC cells (HeyC2) that were 
originally obtained from the ATCC were gifts from Prof. 
MW-Y Chan (National Chung Cheng University, Taiwan). 
Human embryonic kidney 293T (HEK293T) cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (Gibco) 
with 10% FBS and 1% penicillin-streptomycin. All cell 
lines were maintained at 37°C in a humidified atmosphere 
with 5% CO2. Cell line authentication was performed 
according to UKCCCR Guidelines every 3–4 months, 
including mycoplasma detection, DNA –Fingerprinting, 
isozyme detection and cell vitality detection.
A total of 45 tissue specimens, including 30 primary 
epithelial ovarian cancer (PEOC) tissues and 15 benign 
ovarian epithelial tumor tissues, were collected from 
patients who underwent surgery at department of 
Obstetrics and Gynecology, Ren-Ji Hospital, Shanghai 
Jiao Tong University School of Medicine, Shanghai, 
China. All specimens were snap frozen on collection 
within 1 hour of surgery at -80°C and frozen sections 
were cut and mounted on slides. The slides were stained 
with H&E and examined by a pathologist to ensure >85% 
presence of tumor cells. Among the 30 PEOC tissue 
specimens, 10 tumors were determined to be stage I–II 
and 20 tumors were determined to be stage III–IV high 
grade serous ovarian cancer. All samples were collected 
at surgery and prior to chemotherapy. Written informed 
consent was obtained from each patient, and the use of 
clinical specimens was approved by the Institutional 
Ethics Committee.
RNA extraction and quantitative  
real-time RT-PCR
Total RNA was extracted using TRIzol reagent 
(Applied Biosystems, Foster City, CA). Complementary 
DNA was synthesized with Reverse Transcription kit 
(Applied Biosystems). Quantitative reverse transcription-
polymerase chain reaction (RT-PCR) analyses were 
performed in triplicate with the SYBR® Green PCR 
Master Mix (TaKaRa, Otsu, Shiga, Japan) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was used as an internal control. The data analysis was 
performed using the 2-ΔΔCT method as ΔΔCT = (CTTarget1-
CTGAPDH) - (CTTarget2-CTGAPDH).
The miRNA fraction in tumor tissues and cells was 
extracted with miRNA isolation kit (Applied Biosystems). 
MiRNA-specific reverse transcription was performed with 
TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems). Quantitative RT-PCR was performed 
using TaqMan® Universal PCR Master Mix (Applied 
Biosystems) on an ABI 7300HT real-time PCR system 
(Applied Biosystems), and U6 small nuclear RNA was 
used as an internal control.
Plasmid construction
The pCMV6-Rab22a vector and negative control 
pCMV6-NC vector were amplified from OriGene 
(Rockville, MD). The short hairpin RNA interfering 
vector (pLenti-shRab22a) and nontarget control 
vector (pLenti-NC) were purchased from Thermo 
Scientific (South Logan, UT). The human Pre-miR-373 
sequence was amplified from normal human genomic 
DNA and cloned into pMSCV vector to generate pMSCV-
miR-373.
In the luciferase reporter vector, the wild-type or 
mutant 3'-UTR of Rab22a was cloned into the downstream 
of the renilla luciferase gene in the psiCHECK2 vector 
(Promega, Madison, WI). Other potential target genes 
were cloned in a similar manner.
Transient transfection and stable transfection
Rab22a siRNAs were purchased from GenePharma 
(Shanghai, China). Anti-miR-373 inhibitor (anti-miR-373) 
and negative control (anti-miR-NC) were purchased from 
Ambion (Life Technologies, Foster City, CA). Cells were 
transiently transfected with oligo nucleic acid or vectors 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and 
were used 48 h posttransfection.
Virus particles were harvested from HEK293T 
cells 48 h after transfection with pMSCV-miR-373 or 
pLenti-shRab22a with the packaging plasmids using 
Lipofectamine 2000. SKOV3 cells were infected with 
virus supernatant fluid with 8 µg/mL polybrene and 
selected in puromycin for 72 h at 1.5 mg/mL.
Luciferase assay
After 48 h of transfection, cells were lysed with 
1× reporter lysis buffer and firefly and renilla luciferase 
activities were measured using the Dual-Luciferase® 
Reporter kit (Promega) according to the manufacturer’s 
instructions. Firefly luciferase activity was standardized 
to the renilla activity as a control.
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In vitro migration, invasion, and wound scratch 
assays
SKOV3 and A2780 cells were transfected with 
miR-373 (negative control precursor) or Rab22a siRNA 
(or negative control precursor). For the transwell invasion 
assay, 1 × 105 cells per chamber for SKOV3 and 1.5 × 105 
cells per chamber for A2780 were plated (BD Biosciences, 
Franklin Lakes, NJ). Cells were allowed to invade through 
the matrigel-coated inserts at 37°C for 16 h (SKOV3 cells) 
or 30 h (A2780 cells). For the migration assays, 5 × 104 
SKOV3 cells or A2780 cells were plated into each 
chamber without matrigel for 12 h. Cell migration and 
invasion were determined by counting five random fields 
at high-power (Olympus Corp., Tokyo, Japan).
For the wound scratch assay, 5 × 106 SKOV3 cells 
that stably overexpressed either miR-373 or empty vector 
were plated and grown until confluent state and then 
cells were scratched using sterile tips. Cellular migration 
(toward the scratched area) was assessed after 24 h.
In vivo metastasis assays
Female BALB/c nu/nu mice aged 6 weeks were kept 
under pathogen-free conditions according to Shanghai 
Medical Experimental Animal Care guidelines. Animal 
protocols were approved by the Institutional Animal Care 
and Use Committee of Shanghai JiaoTong University 
School of Medicine. Ovarian cancer SKOV3 cells stably 
transfected with the Luc gene (SKOV3luc) were generated. 
For the in vivo metastasis assays, eight mice in each 
group were injected i.p. with 5 × 106 SKOV3luc-pMSCV-
miR-373 cells in 200 µL PBS and SKOV3luc-pMSCV-NC 
cells as control, respectively. Each week all mice were 
anesthetized and given an i.p. injection of D-luciferin 
(GoldBio Technology, St. Louis, MO) and 10–15 min after 
the injection, bioluminescence images were captured with 
IVIS Spectrum (Xenogen, Shrewsbury, MA). Five weeks 
after i.p. injection, the mice were killed and the number of 
visible tumors in the cavity was counted.
Western blotting
For the protein expression analyses, cells were 
lysed with 1 × SDS. Proteins were separated on 8-15% 
SDS-polyacrylamide gel electrophoresis and transferred 
onto polyvinylidene difluoride membranes (Millipore, 
Billerica, MA). Immunoblots were performed with primary 
monoclonal antibodies Rab22a (Abcam, Cambridge, UK), 
E-cadherin (R&D Systems, Minneapolis, MN), N-cadherin 
(BD Biosciences) and β-actin antibodies (Sigma-Aldrich, 
St. Louis, MO). Later the blots were incubated with 
horseradish peroxidase-linked goat-anti-mouse or goat-
anti-rabbit secondary antibody (Abcam). The signals 
were detected by ChemiLucent ECL Detection system 
(Millipore). The results of Western blots were analyzed 
by the Image J program.
Immunohistochemical staining
Immunohistochemical (IHC) staining was 
performed on 5-μm sections of paraffin-embedded 
human EOC tissues and benign ovarian tumor tissue 
to determine the expression of Rab22a using Rab22a 
antibody (Abcam). Briefly, the slides were incubated in 
1 mg/mL Rab22a antibody (1:50) overnight. The sections 
were then incubated with biotinylated anti-rabbit antibody 
for 1 h followed by treatment with 3,3′-diaminobenzidine 
(Sigma-Aldrich) working solution and counterstaining 
with hematoxylin. Scoring was based on the proportion of 
positively stained cells: <5% was scored as 0; 5–24% was 
scored as 1; 25–49% was scored as 2; 50–74% was scored 
as 3; and >74% was scored as 4.
Microarray analysis
The SKOV3 cells were transfected with pMSCV-NC 
vector and pMSCV-miR-373 as described above. Total 
RNA was isolated and labeled. The 35k human Genome 
array (CapitalBio, Beijing, China) was used for gene 
expression analysis. The microarray data were were 
analysed using SpotDataT Pro V3.0. Differentially 
expressed genes were identified through the fold change 
set at <0.5-fold (down-regulated) or >2 (up-regulated) 
change. Microarray analysis was performed using one 
biological replicate.
Statistical analysis
All the experiments were carried out at least in 
triplicate. The data were presented as mean ± standard 
deviation. The differences between two groups were 
analyzed using the double-sided Student’s t-test. The 
statistical analyses of cases in groups were performed 
with the Chi-square test. P < 0.05 indicated a statistically 
significant difference.
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